嵌合抗原受体自然杀伤细胞免疫疗法治疗癌症的进展与挑战
Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer.
作者信息
Rafei Hind, Rezvani Katayoun
机构信息
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
Br J Haematol. 2025 Feb;206(2):443-446. doi: 10.1111/bjh.19939. Epub 2024 Dec 2.
Abstract
Chimeric antigen receptor (CAR)-natural killer (NK)-cell therapy has emerged as a promising strategy in the treatment of haematological malignancies and solid cancers. Leveraging the innate immune properties of NK cells, CAR-NK-cell therapies offer potential advantages for cell therapy, including safety of use in the allogeneic setting and reduced risk of toxicity. This Nutshell provides an overview of the latest advancements in CAR-NK-cell therapy and the challenges that remain.
摘要
嵌合抗原受体（CAR）自然杀伤（NK）细胞疗法已成为治疗血液系统恶性肿瘤和实体癌的一种有前景的策略。利用NK细胞的固有免疫特性，CAR-NK细胞疗法为细胞治疗提供了潜在优势，包括在同种异体环境中使用的安全性和降低的毒性风险。本概述介绍了CAR-NK细胞疗法的最新进展以及仍然存在的挑战。
相似文献
1
Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer.嵌合抗原受体自然杀伤细胞免疫疗法治疗癌症的进展与挑战
Br J Haematol. 2025 Feb;206(2):443-446. doi: 10.1111/bjh.19939. Epub 2024 Dec 2.
2
Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.嵌合抗原受体 (CAR) 自然杀伤 (NK) 细胞疗法：利用先天免疫的力量。
Br J Haematol. 2021 Apr;193(2):216-230. doi: 10.1111/bjh.17186. Epub 2020 Nov 20.
3
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.嵌合抗原受体工程化自然杀伤细胞用于癌症免疫治疗。
J Hematol Oncol. 2020 Dec 7;13(1):168. doi: 10.1186/s13045-020-00998-9.
4
CAR-NK cell therapy: promise and challenges in solid tumors.嵌合抗原受体自然杀伤细胞（CAR-NK）疗法：实体瘤治疗中的前景与挑战
Front Immunol. 2025 Apr 7;16:1574742. doi: 10.3389/fimmu.2025.1574742. eCollection 2025.
5
Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.嵌合抗原受体肿瘤免疫治疗的改革：重定向自然杀伤细胞。
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):200-215. doi: 10.1016/j.bbcan.2018.01.005. Epub 2018 Jan 31.
6
CAR-NK Cells: From Natural Basis to Design for Kill.嵌合抗原受体自然杀伤细胞：从天然基础到杀伤设计。
Front Immunol. 2021 Dec 14;12:707542. doi: 10.3389/fimmu.2021.707542. eCollection 2021.
7
CAR-expressing NK cells for cancer therapy: a new hope.嵌合抗原受体 NK 细胞治疗肿瘤：新希望。
Biosci Trends. 2020 Nov 4;14(5):354-359. doi: 10.5582/bst.2020.03308. Epub 2020 Sep 6.
8
Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.嵌合抗原受体自然杀伤细胞疗法：当前进展及克服挑战的策略。
Front Immunol. 2024 Apr 25;15:1384039. doi: 10.3389/fimmu.2024.1384039. eCollection 2024.
9
CAR-NK cells: A promising cellular immunotherapy for cancer.嵌合抗原受体自然杀伤细胞：癌症有前途的细胞免疫疗法。
EBioMedicine. 2020 Sep;59:102975. doi: 10.1016/j.ebiom.2020.102975. Epub 2020 Aug 24.
10
[Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].[同种异体嵌合抗原受体自然杀伤细胞：自体嵌合抗原受体T细胞的一种有前景的替代方案——现状、自然杀伤细胞来源、局限性与前景]
Bull Cancer. 2021 Oct;108(10S):S81-S91. doi: 10.1016/j.bulcan.2021.06.007.
本文引用的文献
1
CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.CRISPR/Cas9 编辑 NKG2A 提高了原代 CD33 导向嵌合抗原受体自然杀伤细胞的疗效。
Nat Commun. 2024 Sep 30;15(1):8439. doi: 10.1038/s41467-024-52388-1.
2
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD.白细胞介素-21 工程通过 CEBPD 增强 NK 细胞对神经胶质瘤的活性。
Cancer Cell. 2024 Aug 12;42(8):1450-1466.e11. doi: 10.1016/j.ccell.2024.07.007.
3
CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer.CAR 记忆样 NK 细胞靶向间皮素的膜近端结构域，在卵巢癌中表现出有前景的活性。
Sci Adv. 2024 Jul 12;10(28):eadn0881. doi: 10.1126/sciadv.adn0881.
4
Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells.阻断 TGF-β 信号通路是人类诱导多能干细胞来源的 NK 细胞有效杀伤肝癌细胞所必需的。
Cell Stem Cell. 2024 Sep 5;31(9):1327-1343.e5. doi: 10.1016/j.stem.2024.06.009. Epub 2024 Jul 9.
5
Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping.通过转录参考图谱对肿瘤浸润自然杀伤细胞进行泛癌分析。
Nat Immunol. 2024 Aug;25(8):1445-1459. doi: 10.1038/s41590-024-01884-z. Epub 2024 Jul 2.
6
High-dimensional single-cell analysis of human natural killer cell heterogeneity.人类自然杀伤细胞异质性的高维单细胞分析
Nat Immunol. 2024 Aug;25(8):1474-1488. doi: 10.1038/s41590-024-01883-0. Epub 2024 Jul 2.
7
Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation.细胞因子通过表观遗传重编程和转录调控驱动记忆样自然杀伤细胞亚群的形成。
Sci Immunol. 2024 Jun 28;9(96):eadk4893. doi: 10.1126/sciimmunol.adk4893.
8
In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy.肿瘤浸润原发性自然杀伤细胞的体内腺相关病毒-睡眠呼吸暂停综合征-成簇规律间隔短回文重复序列筛选确定了嵌合抗原受体自然杀伤细胞疗法的基因检查点。
Nat Biotechnol. 2025 May;43(5):752-761. doi: 10.1038/s41587-024-02282-4. Epub 2024 Jun 25.
9
CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis.CD28 共刺激增强了 NK 细胞中的 CAR 信号，通过 LCK/CD3ζ/ZAP70 信号轴。
Cancer Discov. 2024 Oct 4;14(10):1879-1900. doi: 10.1158/2159-8290.CD-24-0096.
10
Natural killer cell therapies.自然杀伤细胞疗法。
Nature. 2024 Feb;626(8000):727-736. doi: 10.1038/s41586-023-06945-1. Epub 2024 Feb 21.
Zotero 插件